The U.S. Food and Drug Administration (FDA) has approved Idvynso — a combination of doravirine and islatravir — as a new once-daily, two-drug HIV treatment for adults whose virus is already under control on their current medications. The treatment comes as a single tablet.

Many HIV treatment plans use three drugs. Idvynso offers a two-drug option that also does not include tenofovir or an integrase inhibitor, which can be helpful for some people who need a different fit.

Share your thoughts.

🗳️ Have you tried a once-daily tablet for controlling HIV?

Yes, and it worked for me.

Yes, but it did not work for me.

No, but I am interested in trying one.

No, and I am not interested in trying one.

Thanks! You've successfully submitted your vote.

Sign up to view the results!

Continue with Facebook

Continue with Google

Continue with Email

By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.

Already a member? Log In

What Is Idvynso?

Idvynso combines two types of antiretroviral medicines that work in different ways to stop HIV from making copies of itself:

• Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
• Islatravir is a newer type of nucleoside reverse transcriptase inhibitor (NRTI).

Together, the medications help keep the virus suppressed.

What Did Clinical Trials Find?

The FDA approval was based on results from two phase 3 clinical trials involving more than 1,000 adults living with HIV.

In one study, people switched from the three-drug regimen of bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy) to Idvynso. After 48 weeks, about 92 percent of people taking Idvynso maintained viral suppression, compared with 94 percent of those who stayed on Biktarvy.

In another study, participants switched from one of several different oral HIV regimens to Idvynso. Researchers found that 96 percent of people taking the new treatment maintained an undetectable viral load after 48 weeks, compared with 92 percent of people who stayed on their previous regimen.

What Are the Potential Side Effects?

Like all medications, Idvynso can cause side effects.

The most commonly reported side effects in clinical trials included:

• Diarrhea
• Dizziness
• Fatigue
• Headache
• Abdominal bloating
• Weight increase

Rare but serious side effects included severe skin reactions and drug interactions with certain medications.

People taking HIV treatment should talk with their healthcare team about possible side effects, medication interactions, and the overall risks and benefits of any treatment plan.

Join the Conversation

On myHIVteam, people share their experiences with HIV, get advice, and find support from others who understand.

Does this new two-drug treatment for controlling HIV appeal to you, or are you satisfied with your current treatment plan? Let others know in the comments below.